Issue 1, 21 September 2006 Dear Shareholders Welcome to the September edition of Apollo Life - a regular newsletter to keep you up to date on Apollo Life Sciences' research breakthroughs, latest business developments and more. If you would like any further information, please contact us.   Regards John Priest CEO

IN BRIEF:

Major achievements since our our public listing just over a year ago include: psoriasis treatment: successfully progressed through Phase 1B, preparing for Phase 2 trials proteins business: strengthened, with more products in the market and deeper knowledge of their advantages as research and diagnostic tools needle-free delivery: convenient and comfortable treatments are an R&D focus. We are patenting our transdermal delivery and developing therapeutic and OTC products based on the technology. We have added a new oral delivery platform and have been developing a highly promising oral insulin.

IN THIS ISSUE:

Top diabetes authority applauds Apollo's oral insulin A leading diabetes researcher has praised Apollo Life Sciences for its work to develop an insulin that can be taken orally rather than injected, calling it "the Holy Grail" in treating the disease. Bloody good news: Red Cross to switch to Apollo proteins The Australian Red Cross has indicated its Blood Service will start using one of Apollo Life Sciences' human-based protein products for its blood testing. Apollo's future bright as Board gathers Moss Apollo Life Sciences' value and profile have received a recent boost, with the appointment of high-profile Macquarie Bank executive Bill Moss AM as a non-executive director. Apollo to enter over-the-counter arthritis market, calls for trial volunteers Millions of arthritis sufferers could be the unexpected beneficiaries of Apollo Life Sciences' breakthroughs in anti-inflammatory products.

Click here to subscribe

www.apollolifescience.com

 
Apollo Life Sciences Limited  ASX: AOP
Level 1, 147 Queen Street Beaconsfield NSW 2015 Australia
 
If you would prefer not to receive future email communications from Apollo Life Sciences, please
click here or reply to this message with the word REMOVE in the subject field.
You will receive one additional email confirming your removal.